Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 17, 2022 10:55 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Aprea Therapeutics förvärvar Atrin Pharmaceuticals

STOCKHOLM, SVERIGE 17 maj 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics har förvärvat det privatägda amerikanska bioteknikbolaget Atrin...
May 17, 2022 10:55 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Aprea Therapeutics acquires Atrin Pharmaceuticals

STOCKHOLM, SWEDEN, May 17 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has completed the acquisition of the privately-held US-based...
May 12, 2022 10:30 ET | Source: Karolinska Development AB (publ)

Karolinska Developments årsstämma 2022

STOCKHOLM, SVERIGE – 12 maj 2022. Karolinska Development AB (publ) (”Karolinska Development” eller ”Bolaget”) har den 12 maj 2022 hållit sin årsstämma. Aktieägare har före årsstämman haft möjlighet...
May 12, 2022 10:30 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s Annual General Meeting 2022

STOCKHOLM, SWEDEN – May 12, 2022. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held the Annual General Meeting on May 12, 2022. The shareholders have had the right to...
May 02, 2022 11:04 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Biosergen förbereder klinisk fas 2-studie med BSG005 mot systemisk svampinfektion

STOCKHOLM, SVERIGE 2 maj 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Biosergen förbereder en klinisk fas 2-studie av sin längst utvecklade läkemedelskandidat...
May 02, 2022 11:04 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Biosergen prepares Phase 2 study in mucormycosis infected patients

STOCKHOLM, Sweden, May 2, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Biosergen is preparing a Phase 2 clinical trial of the company’s lead compound...
April 29, 2022 03:00 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Promimics aktie börjar idag handlas på Nasdaq First North Growth Market

STOCKHOLM, SVERIGE 29 april 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att handel med portföljbolaget Promimics aktie inleds idag på Nasdaq First North Growth Market. Aktien...
April 29, 2022 03:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Promimic’s stock starts trading today

STOCKHOLM, Sweden, April 29 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Promimic’s stock starts trading today at Nasdaq First North Growth Market. The...
April 29, 2022 02:00 ET | Source: Karolinska Development AB (publ)

Delårsrapport för januari – mars 2022

STOCKHOLM – den 29 april 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari - mars 2022. Den fulla rapporten är tillgänglig på bolagets hemsida. ...
April 29, 2022 02:00 ET | Source: Karolinska Development AB (publ)

Interim Report - January-March 2022

STOCKHOLM – 29 April 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-March 2022. The full report is available on the Company's website. “With its...